Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1/2 5Phase 3 2Phase 4 1

Status

Completed 133Unknown 57Active not recruiting 32Recruiting 25Terminated 17Withdrawn 4Not yet recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Extrapulmonary Neuroendocrine Cancer 1

Interventions

Paclitaxel 24Oxaliplatin 24Capecitabine 24Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Docetaxel 18Carboplatin 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Specimen Handling 9Pemetrexed 9Radiation 8Injections 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6Trastuzumab 6Topotecan 6Standard of Care 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Etoposide × Clear all
NCT07544654 2026-05-27

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Boehringer Ingelheim

Phase 3 Not yet recruiting
390 enrolled
Endocrine

Extrapulmonary Neuroendocrine Cancer

NCT07502300 2026-04-20

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
562 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡